Search research articles
Contact Us
Filters
Showing results (81-90 of 101) with videos related to
Page
of 11
Sort By:
JCO Precision Oncology
|
July 7, 2022
Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma
Ritesh R Kotecha, Erika Gedvilaite, Ryan Ptashkin, et al.
Journal for Immunotherapy of Cancer
|
November 3, 2022
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
Toni K Choueiri, Harriet Kluger, Saby George, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2021
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Jack P Gleeson, Ines Nikolovski, Renzo Dinatale, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 15, 2021
Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma
Kyrollis Attalla, Renzo G DiNatale, Phillip M Rappold, et al.
European Urology Focus
|
March 2, 2023
Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy
Andrew W Hahn, Ritesh R Kotecha, Paul V Viscuse, et al.
European Urology
|
May 22, 2024
Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146
Chung-Han Lee, Amishi Yogesh Shah, Arpit Rao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 11, 2021
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Meredith M Regan, Opeyemi A Jegede, Charlene M Mantia, et al.
Molecular Cancer Research : MCR
|
May 27, 2021
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab
Chung-Han Lee, Renzo G DiNatale, Diego Chowell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 16, 2022
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Chung-Han Lee, Robert Motzer, Hamid Emamekhoo, et al.
European Urology Oncology
|
February 26, 2023
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma
Bradley McGregor, Daniel M Geynisman, Mauricio Burotto, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 101) with videos related to
Sort By:
Page
of 11
JCO Precision Oncology
|
July 7, 2022
Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma
Ritesh R Kotecha, Erika Gedvilaite, Ryan Ptashkin, et al.
Journal for Immunotherapy of Cancer
|
November 3, 2022
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
Toni K Choueiri, Harriet Kluger, Saby George, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2021
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Jack P Gleeson, Ines Nikolovski, Renzo Dinatale, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 15, 2021
Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma
Kyrollis Attalla, Renzo G DiNatale, Phillip M Rappold, et al.
European Urology Focus
|
March 2, 2023
Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy
Andrew W Hahn, Ritesh R Kotecha, Paul V Viscuse, et al.
European Urology
|
May 22, 2024
Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146
Chung-Han Lee, Amishi Yogesh Shah, Arpit Rao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 11, 2021
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Meredith M Regan, Opeyemi A Jegede, Charlene M Mantia, et al.
Molecular Cancer Research : MCR
|
May 27, 2021
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab
Chung-Han Lee, Renzo G DiNatale, Diego Chowell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 16, 2022
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Chung-Han Lee, Robert Motzer, Hamid Emamekhoo, et al.
European Urology Oncology
|
February 26, 2023
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma
Bradley McGregor, Daniel M Geynisman, Mauricio Burotto, et al.
Page
of 11